What is the Dementia Consortium?
The Dementia Consortium is a charity-industry partnership between Alzheimer’s Research UK world leading pharmaceutical companies and partner Contract Research Organisations.
With industry support, projects funded by the Dementia Consortium aim to validate targets for the diseases that cause dementia and progress the most promising targets to early stage drug discovery.
The case for the Dementia Consortium
Neurodegenerative diseases that cause dementia are our biggest medical challenge. Dementia affects 820,000 people in the UK today and nearly 40 million worldwide. As populations age, the worldwide prevalence of dementia is expected to double every twenty years. Millions of lives will be blighted by these diseases. As well as the enormous social cost, neurodegenerative disease carries an enormous economic impact. In the UK alone, dementia has an economic cost of £23bn, which is greater than heart disease and cancer combined. The Dementia Consortium is focused on fast-tracking new treatments to find an answer to the neurodegenerative diseases that cause dementia.
With support from our pharmaceutical partners, the Dementia Consortium is now open for applications. The deadline for expression of interest applications is the 30 November.
If you have any questions about the application process, or would like to talk to someone about your application, please contact us at email@example.com
Please see our statement on COVID-19